In partnership with the Fraunhofer Center for Molecular Biotechnology and the Walter Reid Army Institute for Research, the Sabin Vaccine Institute has successfully expressed the hookworm-derived antigen Na-APR-1. The production of the antigen represents an important step towards developing ahuman hookworm vaccine candidate.
Late last week, iBio announced the production of the antigen. When all manufacturing and testing activities are complete, the finished vaccine candidate will be used in upcoming Phase 1 clinical trials conducted by Sabin later this year.
Hookworm infection, an intestinal parasitic disease most commonly found in sub-Saharan Africa, Southeast Asia and Latin America, affects an estimated 600 million people. Sabin Vaccine Development’s founding program, the Human Hookworm Vaccine Initiative, aims to reduce human suffering caused by human hookworm through research and development, timely dissemination of results, innovation, and advocacy.Breakthrough for Hookworm Vaccine Development